CINECA IRIS Institutional Research Information System

DEL RE, MARZIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 11.178
AS - Asia 5.281
EU - Europa 4.361
SA - Sud America 1.044
AF - Africa 342
OC - Oceania 22
Continente sconosciuto - Info sul continente non disponibili 9
AN - Antartide 1
Totale 22.238
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.907
SG - Singapore 1.889
IT - Italia 1.777
CN - Cina 1.380
HK - Hong Kong 1.024
BR - Brasile 870
SE - Svezia 563
DE - Germania 393
GB - Regno Unito 389
VN - Vietnam 337
BG - Bulgaria 300
CA - Canada 174
FI - Finlandia 171
CI - Costa d'Avorio 156
RU - Federazione Russa 153
AT - Austria 132
TR - Turchia 124
FR - Francia 120
IN - India 118
NL - Olanda 95
JP - Giappone 74
PL - Polonia 68
AR - Argentina 66
KR - Corea 62
SN - Senegal 61
BD - Bangladesh 59
MX - Messico 48
ES - Italia 43
ZA - Sudafrica 41
IQ - Iraq 31
BE - Belgio 30
UA - Ucraina 30
ID - Indonesia 27
EC - Ecuador 25
SA - Arabia Saudita 24
NG - Nigeria 21
VE - Venezuela 21
AU - Australia 16
LT - Lituania 16
UZ - Uzbekistan 16
CO - Colombia 15
MA - Marocco 15
PK - Pakistan 14
UY - Uruguay 14
CZ - Repubblica Ceca 13
KE - Kenya 12
TW - Taiwan 11
PH - Filippine 10
RO - Romania 10
EU - Europa 9
PY - Paraguay 9
AE - Emirati Arabi Uniti 8
CH - Svizzera 8
CL - Cile 8
IL - Israele 8
JM - Giamaica 8
KZ - Kazakistan 8
NP - Nepal 8
PE - Perù 8
TN - Tunisia 8
BO - Bolivia 7
CR - Costa Rica 7
TT - Trinidad e Tobago 7
AL - Albania 6
DO - Repubblica Dominicana 6
IE - Irlanda 6
JO - Giordania 6
PA - Panama 6
LV - Lettonia 5
BJ - Benin 4
DK - Danimarca 4
EG - Egitto 4
HR - Croazia 4
IR - Iran 4
LK - Sri Lanka 4
MY - Malesia 4
NO - Norvegia 4
NZ - Nuova Zelanda 4
SV - El Salvador 4
TH - Thailandia 4
AM - Armenia 3
AZ - Azerbaigian 3
BB - Barbados 3
BF - Burkina Faso 3
BH - Bahrain 3
ET - Etiopia 3
GH - Ghana 3
GR - Grecia 3
GT - Guatemala 3
HU - Ungheria 3
KW - Kuwait 3
LB - Libano 3
LU - Lussemburgo 3
PT - Portogallo 3
RS - Serbia 3
AO - Angola 2
BW - Botswana 2
BY - Bielorussia 2
DZ - Algeria 2
GE - Georgia 2
Totale 22.210
Salva come PNG Salva come JPEG
Città #
Ashburn 1.259
Hong Kong 1.014
Singapore 959
Fairfield 905
Woodbridge 878
Dallas 851
Santa Clara 776
Houston 620
Ann Arbor 584
Chandler 547
Serra 434
Shanghai 421
Seattle 400
San Jose 340
Wilmington 319
Sofia 300
New York 280
Beijing 272
Boardman 264
Cambridge 264
London 236
Los Angeles 191
Florence 180
Princeton 176
Pisa 175
Abidjan 156
Lawrence 147
Medford 120
Vienna 119
Ottawa 106
Munich 97
Milan 96
Hefei 88
Frankfurt am Main 82
Ho Chi Minh City 80
São Paulo 75
Redondo Beach 69
Istanbul 65
San Diego 65
Rome 64
Buffalo 62
Dearborn 62
Dakar 61
Warsaw 61
Des Moines 60
Nanjing 60
Helsinki 56
Dong Ket 52
Seoul 52
Turku 52
Tokyo 50
Turin 46
Hanoi 42
Rio de Janeiro 41
Bremen 39
Ogden 38
Nuremberg 36
Boulder 33
Cascina 32
Phoenix 29
Chicago 28
Izmir 28
Redwood City 28
Brussels 24
Fuzhou 24
Kunming 24
Toronto 24
Düsseldorf 23
Council Bluffs 21
Lagos 21
Washington 21
Brasília 20
Denver 20
Livorno 19
Montreal 19
Nanchang 19
Naples 19
Stockholm 19
Changsha 18
Paris 18
Belo Horizonte 17
Guangzhou 17
San Francisco 17
Brooklyn 16
Columbus 16
Quanzhou 16
Hyderabad 15
Jacksonville 15
Johannesburg 15
Marseille 15
Poplar 15
Chennai 14
Lappeenranta 14
Mexico City 14
Tashkent 14
Boston 13
Hebei 13
Montevideo 13
Riyadh 13
Shenyang 13
Totale 15.770
Salva come PNG Salva come JPEG
Nome #
Mathematical modeling of drug resistance due to KRAS mutation in colorectal cancer 434
PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC 313
Pharmacogenetic interaction analysis of VEGFR-2 and IL-8 polymorphisms in advanced breast cancer patients treated with paclitaxel and bevacizumab. 282
The Droplet Digital PCR: A New Valid Molecular Approach for the Assessment of B-RAF V600E Mutation in Hairy Cell Leukemia 223
Protein kinase inhibitors for the treatment of advanced and progressive radiorefractory thyroid tumors: From the clinical trials to the real life 204
Association of KRAS mutations in cell-free circulating tumor DNA with occurrence of resistance to TKIs in NSCLC 203
Effects of Amiodarone, Thyroid Hormones and CYP2C9 and VKORC1 Polymorphisms on Warfarin Metabolism: A Review of the Literature. 202
Contribution of KRAS mutations and c.2369C > T (p.T790M) EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: a study on circulating tumor DNA 195
Comparison of digital PCR systems for the analysis of liquid biopsy samples of patients affected by lung and colorectal cancer 193
Early changes in plasma DNA levels of mutant KRAS as a sensitive marker of response to chemotherapy in pancreatic cancer 187
Methods: For studying pharmacogenetic profiles of combination chemotherapeutic drugs 184
Overexpression of TK1 and CDK9 in plasma-derived exosomes is associated with clinical resistance to CDK4/6 inhibitors in metastatic breast cancer patients 181
The amount of activating EGFR mutations in circulating cell-free DNA is a marker to monitor osimertinib response 180
The emerging role of liquid biopsy in diagnosis, prognosis and treatment monitoring of pancreatic cancer 179
DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patients 178
Synergistic interaction between PPAR ligands and salbutamol on human bronchial smooth muscle cell proliferation. 175
Identification of a targetable KRAS-mutant epithelial population in non-small cell lung cancer 175
Concise Review: Chronic Myeloid Leukemia: Stem Cell Niche and Response to Pharmacologic Treatment 174
Pharmacokinetic Markers of 5-Fluorouracil Toxicity in Clinical Trials and Real World 171
DPYD and UGT1A1 genotyping to predict adverse events during first-line FOLFIRI or FOLFOXIRI plus bevacizumab in metastatic colorectal cancer 169
Pharmacokinetic and pharmacogenetic predictive markers of irinotecan activity and toxicity 168
AR-V7 and AR-FL expression is associated with clinical outcome: a translational study in patients with castrate resistant prostate cancer 168
Gene-network analysis predicts clinical response to immunotherapy in patients affected by NSCLC 166
Patients with NSCLC may display a low ratio of p.T790M vs. activating EGFR mutations in plasma at disease progression: implications for personalised treatment 166
Molecular analysis of cell-free circulating DNA for the diagnosis of somatic mutations associated with resistance to tyrosine kinase inhibitors in non-small-cell lung cancer. 165
Droplet digital PCR represents a new sensitive method for detecting B-RAFV600E mutation at diagnosis and during the follow-up of patients affected by hairy cell leukemia 165
Optimized granulocyte colony-stimulating factor prophylaxis in adult cancer patients: from biological principles to clinical guidelines 164
Application of a pharmacokinetic/pharmacogenetic approach to assess the nicotine metabolic profile of smokers in the real-life setting 164
Prediction of fluoropyrimidine toxicities by screening DPYD genetic variants. 163
Diagnosis and treatment monitoring in breast cancer: how liquid biopsy can support patient management 162
The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients 161
Understanding the Mechanisms of Resistance in EGFR-Positive NSCLC: From Tissue to Liquid Biopsy to Guide Treatment Strategy 161
Clinical pharmacology of intravitreal anti-VEGF drugs 160
ANKRd44 gene silencing: A putative role in trastuzumab resistance in HER2-like breast cancer 159
Critical focus on mechanisms of resistance and toxicity of m-TOR inhibitors in pancreatic neuroendocrine tumors 158
Comparison of Real-Time PCR and Droplet Digital PCR for the Determination of JAK2V617F Mutation in Ph'-Negative Myeloproliferative Neoplasms 158
eNOS polymorphisms as predictors of efficacy of bevacizumab-based chemotherapy in metastatic colorectal cancer: Data from a randomized clinical trial 157
Detection of ALK and KRAS Mutations in Circulating Tumor DNA of Patients With Advanced ALK-Positive NSCLC With Disease Progression During Crizotinib Treatment 157
IDH1 mutation is detectable in plasma cell-free DNA and is associated with survival outcome in glioma patients 156
Pharmacogenetics and metabolism from science to implementation in clinical practice: the example of dihydropyrimidine dehydrogenase. 156
Comparative evaluation of molecular methods for the quantitative measure of torquetenovirus viremia, the new surrogate marker of immune competence 156
Androgen receptor gain in circulating free DNA and splicing variant 7 in exosomes predict clinical outcome in CRPC patients treated with abiraterone and enzalutamide 156
Implications of KRAS mutations in acquired resistance to treatment in NSCLC 155
EGFR signaling pathway as therapeutic target in human cancers 155
Author's reply. 153
Pathophysiology and pharmacological targets of VEGF in diabetic macular edema 151
The increase in activating EGFR mutation in plasma is an early biomarker to monitor response to osimertinib: a case report 150
Circulating Tumor DNA as a Marker of Minimal Residual Disease After Radical Resection of Colorectal Liver Metastases 148
Pharmacogenetics of anti-estrogen treatment of breast cancer 148
Clinical utility of Next Generation Sequencing of plasma cell-free DNA for the molecular profiling of patients with NSCLC at diagnosis and disease progression 144
Prevention of fluoropyrimidine toxicity: do we still have to try our patient's luck? 143
Phosphorylation of AKT and ERK1/2 and mutations of PIK3CA and PTEN are predictive of breast cancer cell sensitivity to everolimus in vitro 143
Uncommon dihydropyrimidine dehydrogenase mutations and toxicity by fluoropyrimidines: A lethal case with a new variant 143
Angiogenic inhibitors in gastric cancers and gastroesophageal junction carcinomas: A critical insight 142
null 142
Pharmacogenetics of androgen signaling in prostate cancer: focus on castration resistance and predictive biomarkers of response to treatment 142
Unusual gastrointestinal and cutaneous toxicities by bleomycin, etoposide, and cisplatin: A case report with pharmacogenetic analysis to personalize treatment 141
Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial 141
From the beginning to resistance: study of plasma monitoring and resistance mechanisms in a cohort of patients treated with osimertinib for advanced T790M-positive NSCLC 141
Comprehensive pharmacogenetic analysis of DPYD, UGT, CDA, and ABCB1 polymorphisms in pancreatic cancer patients receiving mFOLFIRINOX or gemcitabine plus nab-paclitaxel 141
Pharmacogenetic foundations of therapeutic efficacy and adverse events of statins 140
Pharmacogenetics of CYP2D6 and tamoxifen therapy: Light at the end of the tunnel? 140
PI3K mutations detected in liquid biopsy are associated to reduced sensitivity to CDK4/6 inhibitors in metastatic breast cancer patients 139
Gemcitabine plus nab-paclitaxel induces PD-L1 mRNA expression in plasma-derived microvesicles in pancreatic cancer 139
Cetuximab as third-line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma RAS/BRAF wild-type circulating tumor DNA: Individual patient data pooled analysis of CRICKET and CAVE trials 138
Dabrafenib treatment in a patient with BRAF V600E ganglioglioma: circulating exosome-derived cancer RNA supports treatment choice and clinical monitoring 137
Results of a comprehensive pharmacogenetic analysis of dihydropyrimidine dehydrogenase in patients treated with fluoropyrimidines and patterns of polymorphisms partially related to treatment tolerability. 136
Contribution of KRAS mutations and c.2369C > T (p.T790M) EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: a study on circulating tumor DNA 135
EGFR-TKIs in non-small-cell lung cancer: Focus on clinical pharmacology and mechanisms of resistance 134
Molecular analysis of cell-free circulating DNA for the diagnosis of somatic mutations associated with resistance to tyrosine kinase inhibitors in non-small-cell lung cancer 133
Recent advances in epigenomics in NSCLC: Real-time detection and therapeutic implications 132
A multiparametric approach to improve the prediction of response to immunotherapy in patients with metastatic NSCLC 132
Radiomics and liquid biopsy in oncology: the holons of systems medicine 131
Gene network Analysis Defines a Subgroup of Small Cell Lung Cancer patients With Short Survival 129
Primary resistance to osimertinib due to SCLC transformation: Issue of T790M determination on liquid re-biopsy 129
The role of drug-drug interactions in prostate cancer treatment: Focus on abiraterone acetate/prednisone and enzalutamide 129
Genetic variation: effect on prostate cancer 128
Endothelial nitric oxide synthase c.-813C>T predicts for proteinuria in metastatic breast cancer patients treated with bevacizumab-based chemotherapy 128
Genome Wide Association Studies (GWAS) 126
Integrating Liquid Biopsy and Radiomics to Monitor Clonal Heterogeneity of EGFR-Positive Non-Small Cell Lung Cancer 125
Dihydropyrimidine dehydrogenase polymorphisms and fluoropyrimidine toxicity: ready for routine clinical application within personalized medicine? 124
KRAS mutations as potential mechanism of crizotinib acquired resistance: a study on circulating tumor DNA 124
Discovery of novel mutations in the dihydropyrimidine dehydrogenase gene associated with toxicity of fluoropyrimidines and viewpoint on preemptive pharmacogenetic screening in patients 124
Clinical pharmacology and drug-drug interactions of lenvatinib in thyroid cancer 124
Predicting Fluoropyrimidine-Related Toxicity: Turning Wish to Will, The Pamm-Eortc Position 123
Incidence of T790M in Patients With NSCLC Progressed to Gefitinib, Erlotinib, and Afatinib: A Study on Circulating Cell-free DNA 123
Blood-based PD-L1 analysis in tumor-derived extracellular vesicles: Applications for optimal use of anti-PD-1/PD-L1 axis inhibitors 122
Clinical and genetic characterization of dihydropyrimidine dehydrogenase (DPD) deficiency in fluoropyrimidine-treated patients carrying the DPYD*2A allele 120
Recommendations for using molecular assays on liquid biopsy: the first document provided by intersociety Group AIOM, SIF, SIAPEC-IAP, SIBioC 120
Erratum: Clinical pharmacology of monoclonal antibodies targeting PD-1 axis in urothelial cancers 120
Liquid biopsies from pleural effusions and plasma from patients with malignant pleural mesothelioma: A feasibility study 119
Drug-drug interactions in breast cancer patients treated with CDK4/6 inhibitors 118
TK-1, TP, Ang-2, and Tie-2 mRNA expression in plasma-derived microvesicles of chemo-refractory metastatic colorectal cancer patients 116
Crizotinib resensitization by compound mutation 116
Reply to Ugo De Giorgi, Vincenza Conteduca, and Emanuela Scarpi's Letter to the Editor re: Marzia Del Re, Elisa Biasco, Stefania Crucitta, et al. The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients. Eur Urol 2017;71:680–7 114
Total and not bevacizumab-bound vascular endothelial growth factor as potential predictive factors to bevacizumab-based chemotherapy in colorectal cancer 114
CDK4/6 Inhibitors Overcome Endocrine ESR1 Mutation-Related Resistance in Metastatic Breast Cancer Patients 113
null 113
Detection of BRAF and KRAS mutations in DNA released by tumors in peripheral blood by an advanced digital droplet PCR. 113
ErbB in NSCLC as a molecular target: Current evidences and future directions 113
Totale 15.404
Salva come PNG Salva come JPEG
Categoria #
all - tutte 73.946
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 73.946
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021683 0 0 0 0 0 0 114 56 175 78 88 172
2021/20221.508 18 46 22 36 237 268 94 74 100 96 91 426
2022/20232.411 297 323 170 170 193 286 33 156 499 25 229 30
2023/20241.701 99 112 263 81 169 327 96 73 40 85 142 214
2024/20255.808 94 204 68 255 578 648 462 331 624 728 639 1.177
2025/20264.911 497 912 906 952 706 513 425 0 0 0 0 0
Totale 22.761